Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Newron Pharmaceuticals SpA ( (CH:NWRN) ) has provided an announcement.
Newron Pharmaceuticals has highlighted a new peer-reviewed publication in Therapeutic Advances in Psychopharmacology reporting that its investigational drug Evenamide, a novel glutamate modulator, delivers clinically meaningful and durable benefits when used as an add-on to first- or second-generation antipsychotics in patients with schizophrenia who respond inadequately to existing therapies, including those with treatment-resistant schizophrenia. The article consolidates data from multiple randomized clinical trials and underscores Evenamide’s differentiated mechanism of action—targeting glutamatergic dysfunction in the hippocampus rather than dopamine receptors in the basal ganglia—showing improvements not only in core schizophrenia symptoms but also in negative symptoms, social functioning and daily-life participation, alongside a favorable safety and tolerability profile; these findings support Evenamide’s potential as a first-in-class add-on therapy for treatment-resistant patients and bolster Newron’s ongoing ENIGMA-TRS Phase III program, which could significantly strengthen the company’s position in the high-unmet-need schizophrenia market if successful.
The most recent analyst rating on (CH:NWRN) stock is a Hold with a CHF20.00 price target. To see the full list of analyst forecasts on Newron Pharmaceuticals SpA stock, see the CH:NWRN Stock Forecast page.
More about Newron Pharmaceuticals SpA
Newron Pharmaceuticals S.p.A., listed on SIX and Xetra, is a biopharmaceutical company specializing in novel therapies for central and peripheral nervous system diseases, with a particular focus on drug candidates addressing unmet needs in psychiatric and neurological disorders such as schizophrenia.
Average Trading Volume: 165,745
Technical Sentiment Signal: Buy
Current Market Cap: CHF389.9M
Find detailed analytics on NWRN stock on TipRanks’ Stock Analysis page.